Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

[Preprint]. 2023 May 8:2020.08.14.248880. Originally published 2020 Aug 15. [Version 2] doi: 10.1101/2020.08.14.248880

PMC7430570.1; 2020 Aug 15
PMC7430570.2; 2023 May 8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.

PMC Copyright notice

Figure 2. — (A) Treatment of both CoV2pp and VSV-Gpp with elastase in serum-free media. All points are means with SEM bars for samples performed in technical triplicate. Red dotted line marks normalized maximal infection level (100%). (B) AAT and A2M inhibit trypsin-mediated enhancement of CoV2pp. Trypsin-treated pseudoparticles were diluted in serum free media, then used to infect Vero-CCL81 cells in the presence of the indicated concentrations of albumin, AAT, or A2M. Data are from two independent experiments and are presented as percent relative infection where each concentration was normalized to the lowest concentration of the test reagent used. (C) Performed identical to (B), AAT, A2M, and albumin have no effect on VSV-Gpp entry.